Outlook Therapeutics Stock (NASDAQ:OTLK)
Previous Close
$5.16
52W Range
$4.61 - $12.85
50D Avg
$5.72
200D Avg
$7.42
Market Cap
$123.72M
Avg Vol (3M)
$264.02K
Beta
0.63
Div Yield
-
OTLK Company Profile
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
OTLK Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CKPT | Checkpoint Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| EYPT | EyePoint Pharmaceuticals, Inc. |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| OCUP | Ocuphire Pharma, Inc. |
| FBIO | Fortress Biotech, Inc. |
| SELB | Cartesian Therapeutics, Inc. |
| HRTX | Heron Therapeutics, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| SLS | SELLAS Life Sciences Group, Inc. |
| KOD | Kodiak Sciences Inc. |
| EYEN | Eyenovia, Inc. |
| MBIO | Mustang Bio, Inc. |
| CDTX | Cidara Therapeutics, Inc. |